These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 36053612)

  • 41. Acceptability and usability of a paediatric HIV screening tool in high-volume outpatient settings in Malawi, perspectives from caregivers and healthcare workers.
    Katirayi L; Maphosa T; Kudiabor K; Kayira D; Gross J; Hrapcak S; Chamanga R; Nkhoma H; Puleni P; Maida A; Ahimbisibwe A; Woelk G
    BMJ Paediatr Open; 2023 Mar; 7(1):. PubMed ID: 36882230
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Adverse events and adherence to HIV post-exposure prophylaxis: a cohort study at the Korle-Bu Teaching Hospital in Accra, Ghana.
    Tetteh RA; Nartey ET; Lartey M; Mantel-Teeuwisse AK; Leufkens HG; Nortey PA; Dodoo AN
    BMC Public Health; 2015 Jun; 15():573. PubMed ID: 26092496
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Early HIV RNA decay during raltegravir-containing regimens exhibits two distinct subphases (1a and 1b).
    Andrade A; Guedj J; Rosenkranz SL; Lu D; Mellors J; Kuritzkes DR; Perelson AS; Ribeiro RM;
    AIDS; 2015 Nov; 29(18):2419-26. PubMed ID: 26558541
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparative effectiveness of efavirenz, protease inhibitors, and raltegravir-based regimens as first-line treatment for HIV-infected adults: a mixed treatment comparison.
    Vieira MC; Kumar RN; Jansen JP
    HIV Clin Trials; 2011; 12(4):175-89. PubMed ID: 22044854
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Antiretroviral therapy containing raltegravir in HIV-infected pregnant women: Systematic review].
    García-Fernández L; Fiestas F; Vásquez R; Benites C
    Rev Chilena Infectol; 2016 Oct; 33(Suppl 1):60-66. PubMed ID: 28453028
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Factors associated with virological success with raltegravir-containing regimens and prevalence of raltegravir-resistance-associated mutations at failure in the ARCA database.
    Rusconi S; Vitiello P; Adorni F; Bruzzone B; De Luca A; Micheli V; Meraviglia P; Maserati R; Di Pietro M; Colao G; Penco G; Di Biagio A; Punzi G; Monno L; Zazzi M;
    Clin Microbiol Infect; 2013 Oct; 19(10):936-42. PubMed ID: 23289841
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Usefulness of Integrase resistance testing in proviral HIV-1 DNA in patients with Raltegravir prior failure.
    Fernández-Caballero JÁ; Chueca N; Álvarez M; Mérida MD; López J; Sánchez JA; Vinuesa D; Martínez MÁ; Hernández J; García F
    BMC Infect Dis; 2016 May; 16():197. PubMed ID: 27177767
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A safety evaluation of raltegravir for the treatment of HIV.
    de Miguel R; Montejano R; Stella-Ascariz N; Arribas JR
    Expert Opin Drug Saf; 2018 Feb; 17(2):217-223. PubMed ID: 29199485
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Liver Fat, Adipose Tissue, and Body Composition Changes After Switching from a Protease Inhibitor or Efavirenz to Raltegravir.
    Hanttu A; Vuoti S; Kivelä P; Arkkila P; Lundbom N; Hakkarainen A; Lundbom J; Lehtimäki T; Viskari H; Lehtinen V; Pietiläinen KH; Sutinen J
    AIDS Patient Care STDS; 2021 Sep; 35(9):335-341. PubMed ID: 34524919
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Frontline healthcare workers' experiences with personal protective equipment during the COVID-19 pandemic in the UK: a rapid qualitative appraisal.
    Hoernke K; Djellouli N; Andrews L; Lewis-Jackson S; Manby L; Martin S; Vanderslott S; Vindrola-Padros C
    BMJ Open; 2021 Jan; 11(1):e046199. PubMed ID: 33472794
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Key barriers and enablers associated with uptake and continuation of oral pre-exposure prophylaxis (PrEP) in the public sector in Zimbabwe: Qualitative perspectives of general population clients at high risk for HIV.
    Gombe MM; Cakouros BE; Ncube G; Zwangobani N; Mareke P; Mkwamba A; Prescott MR; Bhatasara T; Murwira M; Mangwiro AZ; Prust ML
    PLoS One; 2020; 15(1):e0227632. PubMed ID: 31931514
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Switching to Raltegravir From a Virologically Effective Boosted Protease Inhibitor Regimen: A Comparative Effectiveness Analysis From the French Hospital Database on HIV (FHDH-ANRS CO4).
    Potard V; Simon A; Lacombe JM; Parienti JJ; Costagliola D;
    Clin Infect Dis; 2016 Nov; 63(9):1254-1261. PubMed ID: 27543648
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Switching from twice-daily raltegravir plus tenofovir disoproxil fumarate/emtricitabine to once-daily elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate in virologically suppressed, HIV-1-infected subjects: 48 weeks data.
    Mills A; Crofoot G; Ortiz R; Rashbaum B; Towner W; Ward D; Brinson C; Kulkarni R; Garner W; Ebrahimi R; Cao H; Cheng A; Szwarcberg J
    HIV Clin Trials; 2014; 15(2):51-6. PubMed ID: 24710918
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The effect of switching protease inhibitors to raltegravir on endothelial function, in HIV-infected patients.
    Krikke M; Tesselaar K; van den Berk GEL; Otto SA; Freriks LH; van Lelyveld SFL; Visseren FJL; Hoepelman AIM; Arends JE
    HIV Clin Trials; 2018 Apr; 19(2):75-83. PubMed ID: 29770748
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Dolutegravir (DTG)-containing regimens after receiving raltegravir (RAL) or elvitegravir (EVG): Durability and virological response in a large Italian HIV drug resistance network (ARCA).
    Rusconi S; Adorni F; Tau P; Borghi V; Pecorari M; Maserati R; Francisci D; Monno L; Punzi G; Meraviglia P; Paolucci S; Di Biagio A; Bruzzone B; Mancon A; Micheli V; Zazzi M;
    J Clin Virol; 2018 Aug; 105():112-117. PubMed ID: 29957545
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/mL.
    Madeddu G; Rusconi S; Cozzi-Lepri A; Di Giambenedetto S; Bonora S; Carbone A; De Luca A; Gianotti N; Di Biagio A; Antinori A;
    Infection; 2017 Aug; 45(4):521-528. PubMed ID: 28477212
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Raltegravir blocks the infectivity of red-fluorescent-protein (mCherry)-labeled HIV-1
    Ogata-Aoki H; Higashi-Kuwata N; Hattori SI; Hayashi H; Danish M; Aoki M; Shiotsu C; Hashiguchi Y; Hamada A; Kobayashi H; Ihn H; Okada S; Mitsuya H
    Antiviral Res; 2018 Jan; 149():78-88. PubMed ID: 28893602
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Raltegravir plus two nucleoside analogues as combination antiretroviral therapy in HIV-infected patients who require cancer chemotherapy.
    Casado JL; Machuca I; Bañón S; Moreno A; Moltó J; Rodriguez MA
    Antivir Ther; 2015; 20(7):773-7. PubMed ID: 25879675
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Combination antiretroviral therapy with raltegravir leads to rapid immunologic reconstitution in treatment-naive patients with chronic HIV infection.
    Pallikkuth S; Fischl MA; Pahwa S
    J Infect Dis; 2013 Nov; 208(10):1613-23. PubMed ID: 23922374
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.